IL143768A0 - Increasing brain glucose utilization - Google Patents

Increasing brain glucose utilization

Info

Publication number: IL143768A0
Authority: IL; Israel
Prior art keywords: glucose utilization; brain glucose; nervous system; central nervous; agents
Prior art date: 1998-12-17

Application number

IL14376899A

Other languages

English (en)

Original Assignee

Mindset Biopharmaceuticals Usa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-17

Filing date

1999-12-17

Publication date

2002-04-21

1999-12-17 Application filed by Mindset Biopharmaceuticals Usa filed Critical Mindset Biopharmaceuticals Usa

2002-04-21 Publication of IL143768A0 publication Critical patent/IL143768A0/xx

Links

WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 5
210000004556 brain Anatomy 0.000 title abstract 5
239000008103 glucose Substances 0.000 title abstract 5
239000003795 chemical substances by application Substances 0.000 abstract 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
210000003169 central nervous system Anatomy 0.000 abstract 3
102000004877 Insulin Human genes 0.000 abstract 2
108090001061 Insulin Proteins 0.000 abstract 2
102000000536 PPAR gamma Human genes 0.000 abstract 2
108010016731 PPAR gamma Proteins 0.000 abstract 2
229940125396 insulin Drugs 0.000 abstract 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
208000000044 Amnesia Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
229940122355 Insulin sensitizer Drugs 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
229940123464 Thiazolidinedione Drugs 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
125000002015 acyclic group Chemical group 0.000 abstract 1
230000008499 blood brain barrier function Effects 0.000 abstract 1
210000001218 blood-brain barrier Anatomy 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000006984 memory degeneration Effects 0.000 abstract 1
208000023060 memory loss Diseases 0.000 abstract 1
229960005095 pioglitazone Drugs 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
108091006084 receptor activators Proteins 0.000 abstract 1
150000001467 thiazolidinediones Chemical class 0.000 abstract 1
-1 troglitazone Chemical class 0.000 abstract 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 abstract 1
229960001641 troglitazone Drugs 0.000 abstract 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F42—AMMUNITION; BLASTING
- F42C—AMMUNITION FUZES; ARMING OR SAFETY MEANS THEREFOR
- F42C15/00—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges
- F42C15/24—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges wherein the safety or arming action is effected by inertia means
- F42C15/26—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges wherein the safety or arming action is effected by inertia means using centrifugal force

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

IL14376899A 1998-12-17 1999-12-17 Increasing brain glucose utilization IL143768A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11266998P	1998-12-17	1998-12-17
US12225899P	1999-02-24	1999-02-24
PCT/US1999/030066 WO2000035437A2 (fr)	1998-12-17	1999-12-17	Utilisation accrue de glucose par le cerveau

Publications (1)

Publication Number	Publication Date
IL143768A0 true IL143768A0 (en)	2002-04-21

Family

ID=26810226

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL14376899A IL143768A0 (en)	1998-12-17	1999-12-17	Increasing brain glucose utilization
IL143768A IL143768A (en)	1998-12-17	2001-06-14	Pharmaceutical preparations for increasing brain glucose utilization

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL143768A IL143768A (en)	1998-12-17	2001-06-14	Pharmaceutical preparations for increasing brain glucose utilization

Country Status (8)

Country	Link
EP (1)	EP1140081B1 (fr)
JP (1)	JP2002532416A (fr)
AT (1)	ATE476978T1 (fr)
AU (3)	AU2192000A (fr)
CA (1)	CA2355645A1 (fr)
DE (1)	DE69942672D1 (fr)
IL (2)	IL143768A0 (fr)
WO (1)	WO2000035437A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0030845D0 (en) *	2000-12-18	2001-01-31	Smithkline Beecham Plc	Novel treatment
WO2003053926A1 (fr)	2001-12-13	2003-07-03	Ajinomoto Co.,Inc.	Nouveau derive de phenylalanine
US6716842B2 (en)	2002-04-05	2004-04-06	Warner-Lambert Company, Llc	Antidiabetic agents
EP1940403A2 (fr) *	2005-09-22	2008-07-09	SB Pharmco Puerto Rico Inc.	Procede d'amelioration de la fonction cognitive
EP2162127A1 (fr) *	2007-05-24	2010-03-17	SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.	Composition utile pour la prévention d'un effet secondaire dû à l'utilisation d'agonistes de ppar-gamma
WO2010068750A2 (fr) *	2008-12-11	2010-06-17	Board Of Trustees Of Leland Stanford Junior University	Compositions et procédé pour le traitement des perturbations de l'humeur et des déficiences cognitives
US20130203848A1 (en)	2010-06-16	2013-08-08	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Compounds useful for increasing neurogenesis in neural tissue
JP6735224B2 (ja)	2016-01-28	2020-08-05	花王株式会社	アストロサイトのグルコース代謝活性化剤
US12274703B2 (en)	2017-12-21	2025-04-15	Gliapharm Sa	Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en)	2017-12-21	2025-05-27	Gliapharm Sa	Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
WO2020132378A2 (fr)	2018-12-22	2020-06-25	Gliapharm Sa	Compositions et méthodes de traitement de troubles neurologiques comprenant la dépression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4540564A (en) *	1982-05-18	1985-09-10	University Of Florida	Brain-specific drug delivery
US5039794A (en) *	1986-09-19	1991-08-13	Otsuka Pharmaceutical Co., Ltd.	Tumor egress factor and processes for producing the same
IT1260155B (it) *	1992-08-03	1996-03-28	Fidia Spa	Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
GB9604242D0 (en) *	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
CN1280574A (zh) *	1997-10-27	2001-01-17	雷迪研究基金会	新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
EP1051403A1 (fr) *	1998-01-29	2000-11-15	Dr. Reddy's Research Foundation	Nouveaux acides alcanoiques et leur utilisation en medecine, leur procede de preparation et compositions pharmaceutiques les contenant
JP2002507543A (ja) *	1998-05-27	2002-03-12	ドクター・レディーズ・リサーチ・ファウンデーション	二環系化合物、その製造方法およびそれらを含有する薬学的組成物
GB9822473D0 (en) *	1998-10-16	1998-12-09	Glaxo Group Ltd	Chemical compounds
EP1123292A1 (fr) *	1998-10-21	2001-08-16	Novo Nordisk A/S	Nouveaux composes, leur preparation et leur utilisation
WO2000023451A1 (fr) *	1998-10-21	2000-04-27	Novo Nordisk A/S	Nouveaux composes, leur preparation et leur utilisation
EP1123269A1 (fr) *	1998-10-21	2001-08-16	Novo Nordisk A/S	Nouveaux composes, leur preparation et leur utilisation
JP2002527502A (ja) *	1998-10-21	2002-08-27	ノボノルディスクアクティーゼルスカブ	新規化合物、それらの調製及び使用
US6353018B1 (en) *	1998-10-21	2002-03-05	Novo Nordisk A/S	Compounds, their preparation and use
US6028088A (en) *	1998-10-30	2000-02-22	The University Of Mississippi	Flavonoid derivatives
US6191154B1 (en) *	1998-11-27	2001-02-20	Case Western Reserve University	Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

1999
- 1999-12-17 AU AU21920/00A patent/AU2192000A/en not_active Abandoned
- 1999-12-17 AT AT99966359T patent/ATE476978T1/de not_active IP Right Cessation
- 1999-12-17 EP EP99966359A patent/EP1140081B1/fr not_active Expired - Lifetime
- 1999-12-17 CA CA002355645A patent/CA2355645A1/fr not_active Abandoned
- 1999-12-17 JP JP2000587758A patent/JP2002532416A/ja active Pending
- 1999-12-17 DE DE69942672T patent/DE69942672D1/de not_active Expired - Lifetime
- 1999-12-17 IL IL14376899A patent/IL143768A0/xx active IP Right Grant
- 1999-12-17 WO PCT/US1999/030066 patent/WO2000035437A2/fr not_active Ceased
2001
- 2001-06-14 IL IL143768A patent/IL143768A/en not_active IP Right Cessation
2005
- 2005-03-23 AU AU2005201243A patent/AU2005201243A1/en not_active Abandoned
2009
- 2009-01-23 AU AU2009200266A patent/AU2009200266A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE476978T1 (de)	2010-08-15
AU2005201243A1 (en)	2005-04-21
AU2009200266A1 (en)	2009-02-19
CA2355645A1 (fr)	2000-06-22
JP2002532416A (ja)	2002-10-02
EP1140081B1 (fr)	2010-08-11
DE69942672D1 (de)	2010-09-23
WO2000035437A3 (fr)	2000-11-09
AU2192000A (en)	2000-07-03
IL143768A (en)	2008-04-13
EP1140081A2 (fr)	2001-10-10
WO2000035437A2 (fr)	2000-06-22

Legal Events

Date	Code	Title	Description
2008-11-27	FF	Patent granted
2008-11-27	KB	Patent renewed

Publication	Publication Date	Title
IL143768A0 (en)	2002-04-21	Increasing brain glucose utilization
DE69519099D1 (de)	2000-11-16	Aromatische aminoether als schmerzlindernde mittel
DE3687501D1 (de)	1993-02-25	Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
UA70958C2 (uk)	2004-11-15	Спосіб лікування захворювання, пов'язаного з порушенням метаболізму естрогену (варіанти)
ATE202076T1 (de)	2001-06-15	Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
ITMI931714A1 (it)	1995-01-29	Uso del taxol per la produzione di un medicamento per il trattamento delle forme cancerose
EP0225608A3 (fr)	1987-10-28	Médicament
NZ311082A (en)	2000-01-28	Aromatic compounds and pharmaceutical compositions containing same
GEP20032958B (en)	2003-04-25	Adenosine Derivatives
HUT51139A (en)	1990-04-28	Process for production of medical compositions containing as active substance derivatives of 4-substituated imidasole
AU7116681A (en)	1982-12-02	Para-substituted 3-phenoxy-1-alkylamino-propan-2-01 beta receptor blocking compounds
RO116343B1 (ro)	2001-01-30	Compoziţie farmaceutică şi metodă de tratament a infecţiilor bacteriene la pacienţi pediatrici
FR2705343B1 (fr)	1995-07-21	Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
IL84409A0 (en)	1988-04-29	Imidazolidinone derivatives,their preparation and pharmaceutical compositions containing them
US5330978B1 (en)	1996-06-18	Phosphonic acid derivatives and use thereof
KR870007937A (ko)	1987-09-23	2β-치환된 티오 메틸페니실린 유도체 및 그의 제조방법 및 용도
OA07755A (fr)	1985-08-30	Dérivés de triazolo pyrimidine, leur procédé de préparation et leur application thérapeutique en tant que toni-cardiaques.
KR880009944A (ko)	1988-10-06	피페라진 카르복실산, 그의 제조방법 및 그를 함유하는 약학적 조성물
ATE82850T1 (de)	1992-12-15	Verwendung von 2-pyrimidinyl-1-piperazinderivaten.
EP0446921A3 (en)	1992-01-29	Optically active alkylene-dioxybenzene derivatives and their use in therapy
GR3004848T3 (fr)	1993-04-28
FR2696743B1 (fr)	1994-12-23	Nouveaux composés de thiazolidine dione, leur procédé de préparation et les compositions pharmaceutiques les contenant.
ATE28871T1 (de)	1987-08-15	Disubstituierte piperidine,verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE69018099D1 (de)	1995-05-04	Polyamin-Derivate als antineoplastische Mittel.
Ostrowski et al.	1985	Pharmacokinetics of molsidomine in humans